Ergenc I, Kara E, Yilmaz ME, Demirtas CO, Keklikkiran C, Das T, et al
Checked luggage can sit on hot ramps, experience freezing cargo conditions, get delayed, or disappear entirely
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
top of page DETOX YOUR CELLS Nutriswish NutriSwish by Neumi is a potent liquid supplement blending nano glutathione, L-cysteine, curcumin, and vitamin C for maximum absorption
Probiotics and chronic kidney disease
PTD-DBM (0.001%) activates the Wnt/-catenin signaling pathway to encourage new hair follicle growth and prolong the anagen (growth) phase
